652. Ceftazidime-avibactam Alone or as Combination Therapy? Multicenter Retrospective Cohort Analysis of Clinical Outcomes in Patients with Carbapenem-resistant Gram-negative Infection

医学 头孢他啶/阿维巴坦 相伴的 内科学 回顾性队列研究 优势比 碳青霉烯 置信区间 阿维巴坦 逻辑回归 队列 头孢他啶 抗生素 铜绿假单胞菌 微生物学 生物 细菌 遗传学
作者
Ahmed Ullah Mishuk,Jeffrey R. Strich,Sarah Warner,Junfeng Sun,Seidu Malik,Alexander Lawandi,Maiko Kondo,Michael J. Satlin,Aditya Chandorkar,Emily L. Heil,Megan Morales,Anisha Mathur,Joseph Timpone,Darcy Wooten,Daniel A Sweeney,Jonathan Pan,Jillian E. Raybould,Stephanie Bonne,Roberto Viau,Helen W. Boucher,Sara Buckman,Daisuke Furukawa,Daniel Z. Uslan,Samuel F. Hohmann,Sameer S. Kadri
出处
期刊:Open Forum Infectious Diseases [Oxford University Press]
卷期号:9 (Supplement_2) 被引量:1
标识
DOI:10.1093/ofid/ofac492.704
摘要

Abstract Background Ceftazidime-avibactam (caz-avi), a novel β-lactam/β-lactamase inhibitor, is commonly utilized for carbapenem-resistant gram-negative infections (CR-GNI). However, the benefits vs risks of combining caz-avi with other agents are unclear. Methods In this retrospective cohort study, inpatients with CR-GNI treated with caz-avi were identified at 9 U.S. hospitals. The impact of caz-avi monotherapy (MT) or combination therapy (CT; i.e., any concomitant use of gram-negative-active antibiotics) was studied using logistic regression, controlling for baseline patient and hospital factors. The primary outcome was in-hospital mortality or discharge to hospice (death), and secondary outcomes were length of stay (LOS), resolution of infectious signs and symptoms (clinical response), 90-day recurrent infection and future caz-avi–resistant organism. An adjusted odds ratio (aOR) with 95% confidence interval (CI) was used to assess the primary and secondary outcomes. Results 328/499 (65.7%) patients received caz-avi as targeted therapy for a CR-GNI. Overall patients treated with MT and CT were similar at baseline and had comparable baseline demographics although patients treated with CT were more likely to be in the ICU and receive a concomitant empiric in vitro-concordant antibiotic (table 1). The most common organism was Klebsiella spp. (44.6%) followed by Pseudomonas aeruginosa (27.7%) (table 2). Concomitant gram-negative agents are shown in table 3. Overall, 92 (28.1%) patients died and CT (vs MT) displayed similar adjusted mortality risk (27.7% vs 28.7%; aOR [95%CI]: 0.67 [0.34-1.33]) and LOS (19 [9, 37] and 20 [9, 42.5] days). CT (vs MT) was associated with greater odds of clinical response (aOR: 2.25 [95%CI:1.15-4.41]). Among survivors, similar rates of 90-day recurrent infection (50/154 (32.5%) were observed in CT vs 18/82 (22.0%) in MT group (p=0.09) and 5 (2.19%) patients had future infection with a caz-avi–resistant pathogen (3 in CT and 2 in MT group). Conclusion Compared to patients with CR-GNI treated with caz-avi alone, those who received CT including caz-avy had similar survival and LOS but higher clinical response. The role of CT in the era of novel antibiotics warrants additional study. Disclosures Helen W. Boucher, MD, American Society of Microbiology: Honoraria|Elsevier: Honoraria|Sanford Guide: Honoraria.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
mhy完成签到 ,获得积分10
刚刚
cloudehbh完成签到 ,获得积分10
3秒前
张笨笨完成签到 ,获得积分10
4秒前
Zoe完成签到,获得积分10
4秒前
木子完成签到 ,获得积分10
5秒前
活力的鹰完成签到 ,获得积分10
5秒前
乐空思的应助被李麟采纳,获得100
6秒前
嘻嘻哈哈的应助被李麟采纳,获得10
6秒前
8秒前
savesunshine1022完成签到,获得积分10
8秒前
wzk完成签到,获得积分10
9秒前
BAEK完成签到,获得积分10
10秒前
LaixS完成签到,获得积分0
12秒前
敏静发布了新的文献求助10
12秒前
感动的天德完成签到,获得积分10
12秒前
梅梅完成签到 ,获得积分10
13秒前
tt完成签到,获得积分10
14秒前
要笑cc完成签到,获得积分0
14秒前
大熊完成签到 ,获得积分10
14秒前
8D完成签到,获得积分10
14秒前
宣宣宣0733完成签到,获得积分0
16秒前
乖咪甜球球完成签到 ,获得积分10
17秒前
俏皮的莫言完成签到,获得积分10
17秒前
胡质斌完成签到,获得积分0
18秒前
薯片完成签到 ,获得积分10
19秒前
敏静完成签到,获得积分10
22秒前
高妍纯完成签到 ,获得积分10
25秒前
口口完成签到,获得积分20
26秒前
32秒前
xlll完成签到,获得积分10
34秒前
江安弘完成签到,获得积分10
35秒前
000001完成签到,获得积分10
35秒前
范yx发布了新的文献求助10
36秒前
水煮电吹风的应助被xlll采纳,获得10
38秒前
CX完成签到,获得积分10
39秒前
syvshc的应助被科研通管家采纳,获得10
39秒前
Utopian的应助被科研通管家采纳,获得10
39秒前
syvshc的应助被科研通管家采纳,获得10
40秒前
syvshc的应助被科研通管家采纳,获得10
40秒前
cling完成签到 ,获得积分10
40秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185520
求助须知:如何正确求助?哪些是违规求助? 9574253
关于积分的说明 21834609
捐赠科研通 7783129
什么是DOI,文献DOI怎么找? 3434577
关于科研通互助平台的介绍 2558951
邀请新用户注册赠送积分活动 2481357